These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

101 related articles for article (PubMed ID: 11170979)

  • 1. Progressive human immunodeficiency virus-specific immune recovery with prolonged viral suppression.
    Angel JB; Parato KG; Kumar A; Kravcik S; Badley AD; Fex C; Ashby D; Sun E; Cameron DW
    J Infect Dis; 2001 Feb; 183(4):546-54. PubMed ID: 11170979
    [TBL] [Abstract][Full Text] [Related]  

  • 2. RANTES production by T cells and CD8-mediated inhibition of human immunodeficiency virus gene expression before initiation of potent antiretroviral therapy predict sustained suppression of viral replication.
    Fransen S; Copeland KF; Smieja M; Smaill F; Rosenthal KL
    J Infect Dis; 2000 Feb; 181(2):505-12. PubMed ID: 10669333
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The 48-week efficacy of once-daily saquinavir/ritonavir in patients with undetectable viral load after 3 years of antiretroviral therapy.
    Cardiello P; Srasuebkul P; Hassink E; Mahanontharit A; Samor T; Ruxrungtham K; Lange J; Cooper D; Phanuphak P
    HIV Med; 2005 Mar; 6(2):122-8. PubMed ID: 15807718
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Immune reconstitution after 2 years of successful potent antiretroviral therapy in previously untreated human immunodeficiency virus type 1-infected adults.
    Notermans DW; Pakker NG; Hamann D; Foudraine NA; Kauffmann RH; Meenhorst PL; Goudsmit J; Roos MT; Schellekens PT; Miedema F; Danner SA
    J Infect Dis; 1999 Oct; 180(4):1050-6. PubMed ID: 10479130
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A prospective study of efficacy and safety of once-daily saquinavir/ritonavir plus two nucleoside reverse transcriptase inhibitors in treatment-naive Thai patients.
    Ananworanich J; Hill A; Siangphoe U; Ruxrungtham K; Prasithsirikul W; Chetchotisakd P; Kiertiburanakul S; Munsakul W; Raksakulkarn P; Tansuphasawadikul S; Nuesch R; Cooper DA; Hirschel B;
    Antivir Ther; 2005; 10(6):761-7. PubMed ID: 16218176
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Presence of human immunodeficiency virus-1-specific CD4 and CD8 cellular immune responses in children with full or partial virus suppression.
    Papasavvas E; Sandberg JK; Rutstein R; Moore EC; Mackiewicz A; Thiel B; Pistilli M; June RR; Jordan KA; Gross R; Maino VC; Nixon DF; Montaner LJ
    J Infect Dis; 2003 Sep; 188(6):873-82. PubMed ID: 12964119
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Improvement in cell-mediated immune function during potent anti-human immunodeficiency virus therapy with ritonavir plus saquinavir.
    Angel JB; Kumar A; Parato K; Filion LG; Diaz-Mitoma F; Daftarian P; Pham B; Sun E; Leonard JM; Cameron DW
    J Infect Dis; 1998 Apr; 177(4):898-904. PubMed ID: 9534961
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Immune reconstitution in the first year of potent antiretroviral therapy and its relationship to virologic response.
    Connick E; Lederman MM; Kotzin BL; Spritzler J; Kuritzkes DR; St Clair M; Sevin AD; Fox L; Chiozzi MH; Leonard JM; Rousseau F; D'Arc Roe J; Martinez A; Kessler H; Landay A
    J Infect Dis; 2000 Jan; 181(1):358-63. PubMed ID: 10608789
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Safety and antiviral activity at 48 weeks of lopinavir/ritonavir plus nevirapine and 2 nucleoside reverse-transcriptase inhibitors in human immunodeficiency virus type 1-infected protease inhibitor-experienced patients.
    Benson CA; Deeks SG; Brun SC; Gulick RM; Eron JJ; Kessler HA; Murphy RL; Hicks C; King M; Wheeler D; Feinberg J; Stryker R; Sax PE; Riddler S; Thompson M; Real K; Hsu A; Kempf D; Japour AJ; Sun E
    J Infect Dis; 2002 Mar; 185(5):599-607. PubMed ID: 11865416
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Stavudine, lamivudine plus novel protease inhibitor therapy in antiretroviral-naive HIV-infected individuals treated for 24 weeks.
    Murphy RL
    Antivir Ther; 1999; 4 Suppl 3():85-7. PubMed ID: 16021877
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Association of T cell proliferative responses and phenotype with virus control in chronic progressive HIV-1 disease.
    Malhotra U; Bosch RJ; Chan E; Wang R; Fischl MA; Collier AC; McElrath MJ
    J Infect Dis; 2004 Feb; 189(3):515-9. PubMed ID: 14745710
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Baseline HIV-1 RNA level and CD4 cell count predict time to loss of virologic response to nelfinavir, but not lopinavir/ritonavir, in antiretroviral therapy-naive patients.
    King MS; Bernstein BM; Walmsley SL; Sherer R; Feinberg J; Sanne I; Cernohous P; Montaner JS; Brun SC; Sun E
    J Infect Dis; 2004 Jul; 190(2):280-4. PubMed ID: 15216462
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Residual viraemia in HIV-1-infected patients with plasma viral load Ostrowski SR; Katzenstein TL; Pedersen BK; Gerstoft J; Ullum H
    Scand J Immunol; 2008 Dec; 68(6):652-60. PubMed ID: 19055701
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Reductions in viral load and increases in T lymphocyte numbers in treatment-naive patients with advanced HIV-1 infection treated with ritonavir, zidovudine and zalcitabine triple therapy.
    Mathez D; Bagnarelli P; Gorin I; Katlama C; Pialoux G; Saimot G; Tubiana P; De Truchis P; Chauvin JP; Mills R; Rode R; Clementi M; Leibowitch J
    Antivir Ther; 1997 Jul; 2(3):175-83. PubMed ID: 11322272
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Ritonavir-saquinavir dual protease inhibitor compared to ritonavir alone in human immunodeficiency virus-infected patients.
    Michelet C; Ruffault A; Sébille V; Arvieux C; Jaccard P; Raffi F; Bazin C; Chapplain JM; Chauvin JP; Dohin E; Cartier F; Bellissant E
    Antimicrob Agents Chemother; 2001 Dec; 45(12):3393-402. PubMed ID: 11709314
    [TBL] [Abstract][Full Text] [Related]  

  • 16. CD4+ T cell count recovery in HIV type 1-infected patients is independent of class of antiretroviral therapy.
    Khanna N; Opravil M; Furrer H; Cavassini M; Vernazza P; Bernasconi E; Weber R; Hirschel B; Battegay M; Kaufmann GR;
    Clin Infect Dis; 2008 Oct; 47(8):1093-101. PubMed ID: 18783328
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Antiretroviral effect of two different dose regimens of ritonavir and saquinavir on HIV-infected adults in a population-based setting.
    Jahnke N; Seminari E; Hogg RS; Yip B; O'Shaughnessy MV; Montaner JS
    Antivir Ther; 1999; 4(3):151-6. PubMed ID: 12731754
    [TBL] [Abstract][Full Text] [Related]  

  • 18. HIV-1 viral replication below 50 copies/ml in patients on antiretroviral therapy is not associated with CD8+ T-cell activation.
    Steel A; Cox AE; Shamji MH; John L; Nelson M; Henderson DC; Gotch FM; Gazzard BG; Kelleher P
    Antivir Ther; 2007; 12(6):971-5. PubMed ID: 17926652
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Long-term efficacy and safety of first-line therapy with once-daily saquinavir/ritonavir.
    Ananworanich J; Gayet-Ageron A; Ruxrungtham K; Chetchotisakd P; Prasithsirikul W; Kiertiburanakul S; Munsakul W; Raksakulkarn P; Tansuphasawadikul S; LeBraz M; Jupimai T; Ubolyam S; Schutz M; Hirschel B;
    Antivir Ther; 2008; 13(3):375-80. PubMed ID: 18572750
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Durability of response to treatment among antiretroviral-experienced subjects: 48-week results from AIDS Clinical Trials Group Protocol 359.
    Gulick RM; Hu XJ; Fiscus SA; Fletcher CV; Haubrich R; Cheng H; Acosta E; Lagakos SW; Swanstrom R; Freimuth W; Snyder S; Mills C; Fischl M; Pettinelli C; Katzenstein D
    J Infect Dis; 2002 Sep; 186(5):626-33. PubMed ID: 12195349
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.